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parameters with p < 0.001. Compared to MMF, reduced-dose of
CsA with everolimus decreased the one-year total direct medical
cost due to major clinical events by HF 1,373,254 and HF
1,387,057 for everolimus 1.5mg and 3.0mg, respectively (see
table) . Adjusted for patient characteristics, the cost savings
become HF 940,380 for everolimus 1.5mg and HF 838,570 for
everolimus 3.0mg. CONCLUSION: The use of reduced-dose
CsA with everolimus 1.5mg in de novo kidney transplant recip-
ients improves transplant outcomes and reduces one-year total
direct medical cost compared to an MMF based strategy.
PUK6
ECONOMIC IMPACT OF EXTENDED-RELEASE TOLTERODINE
VERSUS IMMEDIATE- AND EXTENDED-RELEASE
OXYBUTYNIN AMONG COMMERCIALLY-INSURED PERSONS
WITH OVERACTIVE BLADDER
Ollendorf D1, Jumadilova Z2,Varadharajan S1, Girase P1
1PharMetrics, Inc, Watertown, MA, USA; 2Pﬁzer, Inc, New York, NY,
USA
OBJECTIVES: To examine the economic impact of extended-
release tolterodine (TOL-ER) versus immediate- (IR) or
extended-release (ER) oxybutynin (OXY) in patients with over-
active bladder (OAB). METHODS: This retrospective cohort
study used the PharMetrics Patient-Centric Database to identify
patients diagnosed with OAB who newly started therapy with
TOL-ER, OXY-IR, or OXY-ER between January 2001 and
December 2002. 12-month pretreatment and follow-up periods
were established from the ﬁrst prescription date. TOL-ER
patients were matched to OXY-IR and OXY-ER patients based
on an estimated propensity score for TOL-ER therapy (i.e., prob-
ability of TOL-ER use based on multiple logistic regression). Use
of OAB pharmaceuticals and related medications; use of outpa-
tient and inpatient services related to OAB, infection, depression,
and other conditions; and all corresponding costs were compiled
for 1 year. Costs were compared using Wilcoxon rank-sum tests,
and total health care costs were validated in a multivariate
context using a generalized linear model. RESULTS: A total of
7257 TOL-ER/OXY-ER (80% female) and 5936 TOL-ER/OXY-
IR (72% female) matched pairs were created (mean age, 54y).
Because of matching, demographic and clinical characteristics
between cohorts were not signiﬁcantly different. Costs for ser-
vices related to OAB, infection, and depression were signiﬁcantly
lower for TOL-ER vs. OXY-ER. Total health care costs were also
signiﬁcantly reduced for TOL-ER (mean [SD], $8303 [$18,802])
vs. OXY-ER ($8862 [$18,864], p = 0.0109). Medication costs
were signiﬁcantly higher for TOL-ER ($2791 [$4997]) than for
OXY-IR ($2204 [$3944], p < 0.0001). However, this increase
was offset by reductions in expenses related to conditions includ-
ing infection and depression. Total costs did not differ signiﬁ-
cantly between TOL-ER and OXY-IR. After adjustment for
between-group differences, costs were signiﬁcantly reduced for
TOL-ER patients versus OXY-ER and OXY-IR (p < 0.01). CON-
CLUSION: Patients with OAB initiating therapy with TOL-ER
incurred lower annual health care costs, including nonpharma-
cologic costs related to OAB, infection, and depression compared
with those receiving OXY-IR or OXY-ER.
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OBJECTIVES: Overactive bladder (OAB) is associated with both
an economic and quality of life burden. Current management
involves antimuscarinic agents. Extended release formulations
are expected to improve treatment compliance and persistence.
This study explored persistence and impact on OAB related co-
morbidities with two therapies: tolterodine extended release
(TER) and oxybutynin immediate release (OIR) compared to no
active drug treatment (NONE) and associated costs across ﬁve
European countries. METHODS: A decision-analytic model esti-
mated costs and outcomes associated with treatment. A large
case-controlled study was used to estimate the percentage of
patients achieving persistent control, deﬁned as patients still on
therapy after six months. Resource use included drug costs,
physician visits, incontinence pads and the cost of urinary tract
and skin infections. The model estimated the cost per patient
achieving persistent control of OAB. Costs were estimated from
the perspective of health service payers over six months. Sensi-
tivity analyses included variation of the resource use frequency
assumptions, cost inputs, and the time horizon of the analysis.
RESULTS: After six months, the proportion of patients achiev-
ing persistent control was 39% on TER and 9% on OIR. Costs
per patient for TER ranged between €349 (Germany) and €772
(Sweden) and between €177 (Germany) and €693 (Sweden) for
OIR. Compared against NONE, the Incremental Cost-Effective-
ness Ratios (ICERs) for TER were much lower than for OIR.
ICERs of TER vs. OIR ranged between €351 (Sweden) and €822
(Spain). Sensitivity analysis highlighted the model’s sensitivity to
the time horizon, physician costs and persistency rates. Differ-
ences in costs largely reﬂect variation in the proportion of
patients in each country using incontinence pads. CONCLU-
SION: In this model more than twice as many patients achieve
persistent control with TER than with OIR. The model estimated
the cost per patient achieving persistent control would be lower
with TER than with OIR.
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OBJECTIVES: Studies showed secondary prevention of cardio-
vascular (CV) events to be cost-effective, but only few reports
proved cost-effectiveness in primary prevention, in particular
with respect to nephrologic markers such as urinary albumin
excretion (UAE). Our objective was to conduct cost-effectiveness
analysis of screening for albuminuria in general population 
and subsequent ACE-inhibitor treatment to prevent CV-events.
METHODS: Data is derived from the PREVEND-IT (Prevention
REnal and Vascular ENdstage Disease Intervention Trial) and the
PREVEND observational-cohort study. The PREVEND-IT was
a randomised placebo-controlled trial to assess the effects of fos-
inopril 20mg on CV-events in 864 subjects with UAE 15–300
mg/24hr, blood pressure <160/100mmHg and plasma choles-
terol <8.0mmol/L. Evaluation of treatment was based on the
PREVEND-IT; the screening part was primarily based on the
observational data (PREVEND) gathered among trial partici-
pants and beyond. Cost-effectiveness was estimated for the
Dutch population. Cost-effectiveness was expressed in net costs
per life-year gained (LYG) with a 4% discounting rate and (sto-
chastic) sensitivity analysis. Bootstrapping analysis was used to
derive 95% CI for the cost-effectiveness ratio (CER) and thresh-
old probabilities. RESULTS: Patients treated with fosinopril
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showed a strong trend for less CV-events (p = 0.098). Cost-
effectiveness of screening for elevated albuminuria was.
€16,559/LYG (from €7,030 to €24,125 in sensitivity analysis).
Stochastic analysis indicated that the probability of cost-
effectiveness below the suggested Dutch threshold for cost-
effectiveness of €20,000 per LYG is 60% in the baseline 
analysis, increasing to 91% if only those subjects are treated with
fosinopril showing a UAE >50mg/24hr. Also, limiting screening
to only those aged greater or equal than 50; improved cost-
effectiveness considerably. CONCLUSION: Primary prevention
by screening the general population for the risk marker albu-
minuria greater or equal to 15mg/24hr and subsequent treat-
ment with fosinopril of those found positive to reduce the
incidence of CV events may well be cost effective.
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OBJECTIVES: To evaluate short-term (12 months) cost-
effectiveness (CE) of intravenous (iv) vitamin D preparations
(paricalcitol and calcitriol) to control hyperparathyroidism in
hemodialysis patients. METHODS: A decision analytic model
was constructed and analysed from the hospital and the Italian
National Health System (INHS) perspectives. Following the indi-
cations of the Italian Nephrology Society on the use of iv Vitamin
D analogues, patients were simulated to start a 12-month iv
Vitamin D treatment when parathormone (PTH) plasmatic level
was >700pg/ml. Starting doses were 27mg/week for paricalcitol
and 9mg/week for calcitriol; subsequent maintenance dose was
adjusted assuming decreasing PTH levels over time. Model para-
meters were derived from multiple published sources. Clinical
course of treatment and efﬁcacy in controlling hyperparathy-
roidism were based on a RCT (Sprague SM. Kidney Int 2003);
effect on survival, hospitalisation rate and length-of-stay (LOS)
were based on retrospective studies (Teng M. NEJM 2003;
Dobrez DG. Nephrol Dial Transplant 2004). Cost included drug
costs (hospital prices excluding taxes), cost per hospitalization
(national mean DRG value, 2002), in the INHS perspective, or
cost per day of hospitalization (general medical ward, Lucioni
C. et al. Treat Endocrinol 2003), in the hospital perspective.
RESULTS: Per patient one-year drug acquisition costs were
€3364.74 for paricalcitol and 1883.25 for calcitriol. Calcitriol
patients had an average of 0,846 hospitalizations/year more than
paricalcitol at an incremental cost, in the INHS perspective
(DRG tariffs), of €2868.69. Calcitriol patients had an average 
of 9.17 hospitalization/days more than paricalcitol at an incre-
mental cost, in the hospital perspective (LOS), of €2249.58. Par-
icalcitol strategy resulted dominant in both perspectives.
Robustness of these ﬁndings was demonstrated in multiple sen-
sitivity analyses. CONCLUSIONS: In Italy, paricalcitol greater
acquisition costs are offset by reduction in hospitalizations 
and LOS both from an NHS perspective and from the hospital
perspective.
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OBJECTIVES: To demonstrate cost-effectiveness (ICER) of
Mimpara (MIM), a drug against secondary hyperparathyroidism
(sHPT) in dialysis, compared to standard treatment of care
(SOC). METHODS: A Markov model operates in 1/2 year cycles
and runs over 16 years until the starting cohort reaches 70 years.
Mortality risk per cycle was calculated from a 2-year cohort dial-
ysis database (n = 13,000)1. The model uses speciﬁc distributions
for parathyroid hormone (PTH), Calcium (Ca) x Phosphor (P),
age, vintage and MIM dosages (30–120mg/day) from phase III
trials. Patients withdrawing from MIM were treated with SOC.
Average drug costs were €3109/year ﬁrst cycle and €2617/year
subsequent cycles as only drug responders (85%) remained on
study drug. Other treatment costs were taken from a retrospec-
tive cost study in Belgium2 using average daily cost of €214 per
dialysis patient plus €50/day for sHPT-sufferer. Annual 3% dis-
count rate was applied to cost and outcome data. RESULTS:
Running the model in Monte-Carlo simulation (10,000 itera-
tions) over 16 years, delivered a mortality difference of 0.17
years favoring MIM-use for an extra cost of €8027 (+ dialysis
cost) resulting in an ICER of €47,218 per Life Year Gained.
Excluding dialysis costs the ICER was €36,970. Sensitivity analy-
ses ranging discount rates from 0% to 6% independently for
both outcome and cost data showed ICERs of €36,970 and
€59,459 for outcome and €64,517 and €35,088 for cost results,
respectively. Evaluating the ICERs over time indicates that cost-
savings may appear early in MIM-treatment (ﬁrst 2 to 3 years)
due to reductions in co-morbidities without observable survival
beneﬁt. CONCLUSION: Including dialysis costs in the ICER-
equation maintained a reasonable CE-result (<€50,000/LYG)
favoring the use of Mimpara for sHPT.
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OBJECTIVES: Kidney transplantation (KT) is generally
acknowledged as the most clinically effective and cost-effective
option in managing ESRD patients. The objective of our study
was to identify costs and estimate cost-effectiveness of various
ESRD treatment modalities in Latvia. METHODS: We retro-
spectively analysed ﬁles of 250 patients in an in-center hemodial-
ysis treatment mode (HD), 60 patients in continuous ambulatory
peritoneal dialysis treatment mode (CAPD) and 51 patients after
successful KT for the ﬁrst 3 years of treatment. All direct medical
costs were registered. Cost-effectiveness was estimated by costs
per 3 life-years gained. RESULTS: Mean direct costs (in 2003 €)
for one patient for the ﬁrst year and all three years of treatment
were: for CAPD 16,250.0 + €1,577.4 and 48,327.7 ± 1, €162.2
respectively, for HD 14,131.7 ± €1,212.4 and 42,052.4 ±
€1,203.2 respectively, and for KT 15,880.0 ± €4,744.7 and
25,460.0 ± €2,994.4 respectively. Average treatment costs per
patient over the 3 years were the highest in the CAPD group (P
< 0.05 vs. HD, P < 0.001 vs. KT) and KT was the least expen-
sive (as expected). The initial higher costs of KT were fully
recouped within 15 months after surgery. Probability of life
expectancy for CAPD, HD and KT for the ﬁrst and third year
were: 77.3%, 84.1% and 91.3% respectively, and 45.0%, 43.l%
and 83.7% (P < 0.001 vs. CAPD and HD), respectively. The cost
of 3 life-years gained by KT was signiﬁcantly less (P < 0.001)
than the cost associated with CAPD and HD (€29,598.5 vs.
€106,661.1 and €97,798.5 respectively). CONCLUSIONS:
Compared to CAPD and HD, KT provided greater survival ben-
